Two decades after a breast cancer vaccine trial, every participant is still alive—an astonishing result for metastatic ...

Women vaccinated against human papillomavirus (HPV) at a young age might be able to limit cervical cancer screening to two or ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

As cervical cancer awareness month concludes, health officials stress the importance of regular screenings and the HPV ...

U.S. guidelines recommend cervical cancer screening every three to five years starting at 21, the CDC says. The American ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.